Trial Profile
International, multicenter, phase II, randomized, parallel-arm trial investigating the role of two different metronomic chemotherapy regimens in locally advanced or metastatic triple negative breast cancer patients (TNBC) as maintenance therapy after first line treatment. VICTOR-3 study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms VICTOR-3 study
- 14 Feb 2018 New trial record